Last updated: 2026-09-16 11:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Bright Minds Biosciences Inc. (DRUG) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $60.50, with a market capitalisation of $621.89M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $44.25 to $123.75. This page covers its latest market performance, valuation, price trends and company information.
$621.89M | |
$61.90 | |
$123.75 | |
$0.93 | |
$63.38 | |
53.16K | |
195.08K | |
-- | |
$123.75 | |
$44.25 | |
-- | |
-- |
Bright Minds Biosciences Inc. (DRUG) is trading at $64.33 in pre-market trading as of 2026-09-15 23:55:00, up 1.50% ($0.95) from the previous close of $63.38
Pre-market trading shows how investors are pricing DRUG before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Bright Minds Biosciences Inc. (DRUG) moved from $65.16 to $60.50, representing a decline of 7.16% ($4.66).
The stock traded between $59.25 and $69.07 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 74.07 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 20.4%
DRUG is currently trading at $60.50, placing it 20.4% of the way from its 52-week low of $44.25 to its 52-week high of $123.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
| Employees | 25 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Bright Minds Biosciences Inc. (DRUG) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.